Cagrilintide

Long-acting amylin analog studied alongside semaglutide as CagriSema.

Overview

Cagrilintide is a 37-amino-acid acylated amylin analog with affinity at all five amylin receptor subtypes. Investigated by Novo Nordisk both as monotherapy and in combination with semaglutide (CagriSema).

Mechanism

Amylin and calcitonin receptor agonism → satiety, slowed gastric emptying.

Research areas

Obesity
Combination metabolic therapy

Related peptides

Semaglutide

Long-acting GLP-1 receptor agonist for glycemic control and weight management.

View

Tirzepatide

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

View

Retatrutide

Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.

View